Evoke PharmaEVOK
About: Evoke Pharma Inc is a specialty pharmaceutical company focused on the development and commercialization of drugs to treat gastrointestinal, or GI, disorders, and diseases. The company's product Gimoti is an investigational metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. Gimoti is a novel nasal spray formulation of metoclopramide designed to provide systemic delivery of the molecule through the nasal mucosa.
Employees: 4
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
19.1% less ownership
Funds ownership: 44.5% [Q2] → 25.4% (-19.1%) [Q3]
31% less funds holding
Funds holding: 16 [Q2] → 11 (-5) [Q3]
51% less capital invested
Capital invested by funds: $2.02M [Q2] → $995K (-$1.03M) [Q3]
63% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 8
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 8
Research analyst outlook
We haven’t received any recent analyst ratings for EVOK.
Financial journalist opinion
Based on 6 articles about EVOK published over the past 30 days
